Data from a systematic review; however, do not show any definitive pattern of unfavorable changes of AIT on plasma-lipoproteins from baseline to follow-up assessments in patients with hormone receptor-positive early breast cancer; however, interpretability is limited by heterogeneity in the patient population, treatment sequence (i.e. initial AIT or a setting with switch between tamoxifen and AIT) and dissimilarities in data collection methods [3]. This evidence concerns the gene NR4A1 and breast cancer.